来曲唑联合紫杉醇加卡铂治疗复发卵巢上皮癌的临床疗效观察  

Observation on clinical effect of letrozole combined with paclitaxel and carboplatin in treatment of recurrent ovarian epithelial carcinoma

作　　者：王学慧[1] 柳春韬 包洪丽[1] 佟春艳[1] 张彩云 李冰[1] 宗建国[1] 于晶[1] WANG Xue-Hui;LIU Chun-Tao;BAO Hong-Li(Affiliated Zhongshan Hospital of Dalian University,Dalian,Liaoning 116001,China)

机构地区：[1]大连大学附属中山医院,辽宁大连116001

出　　处：《中国妇幼保健》2021年第23期5370-5373,共4页Maternal and Child Health Care of China

基　　金：辽宁省大连市卫生和计划生育委员会资助项目(2016107)。

摘　　要：目的探讨来曲唑联合紫杉醇加卡铂治疗复发卵巢上皮癌的临床疗效,为临床治疗提供参考依据。方法回顾性分析2015年1月—2017年12月采用来曲唑联合紫杉醇加卡铂治疗复发卵巢上皮癌的患者。对照组(T+C):行紫杉醇和卡铂的联合化疗。每3周1次。紫杉醇175 mg/m^(2);卡铂:[内生肌酐清除率(CCR)+25]×AUC(血药浓度-时间曲线下的面积)(AUC=5),最大剂量不超过500 mg(国产),450 mg(进口)。观察组(T+C+L):入组后立即开始长期口服来曲唑,1次/d, 1片/次(2.5 mg)。同时行上述标准的紫杉醇和卡铂的联合化疗。每3周1次。结果观察组(T+C+L)的6个月、12个月、18个月及24个月平均生存率分别为100.00%、89.47%、84.21%及63.16%,对照组(T+C)的6个月、12个月、18个月及24个月平均生存率分别为88.89%、77.78%、50.00%及27.78%。观察组(T+C+L)平均生存率明显高于对照组(T+C),差异有统计学意义(P<0.05)。观察组(T+C+L)平均有效率(ORR)高于对照组(T+C),但差异无统计学意义(P>0.05)。毒副反应几乎是基于紫杉醇的严重过敏毒性反应,其次是紫杉醇联合卡铂的骨髓抑制,手足麻木、肌肉关节疼痛等,均有不同程度的脱发及少数患者的潮热、盗汗等,并未出现其他严重过敏反应。两组间毒副反应差异无统计学意义(P>0.05)。结论观察组(T+C+L)较对照组(T+C)在治疗复发卵巢上皮癌时,有较高的疗效,无明显增加毒副反应,在改善患者生存质量,延长患者生存周期方面更加优越。Objective To explore the clinical effect of letrozole combined with paclitaxel and carboplatin in treatment of recurrent ovarian epithelial carcinoma, provide a reference basis for clinical treatment.Methods The patients with recurrent ovarian epithelial carcinoma treated by letrozole combined with paclitaxel and carboplatin from January 2015 to December 2017 were analyzed retrospectively.In control group(T+C), the patients were treated with paclitaxel(175 mg/m^(2)) combined with carboplatin, per time every three weeks, carboplatin: [endogenous creatinine clearance rate(CCR)+25]×AUC(blood concentration-area under time curve)(AUC=5), the maximum doses were no more than 500 mg(made in China) and 450 mg(imported drug), respectively.In observation group(T+C+L), the patients were treated with oral administration of letrozole, once a day, one pill per time(2.5 mg), then paclitaxel and carboplatin were used, the method was the same as control group, per time every three weeks.Results The every survival rates at 6, 12, 18, and 24 months in observation group(T+C+L) were 100.00%, 89.47%, 84.21%, and 63.16%, respectively.The every survival rates at 6, 12, 18, and 24 months in control group(T+C) were 88.89%, 77.78%, 50.00%, and 27.78%,respectively.The every survival rate in observation group(T+C+L) was statistically significantly higher than that in control group(T+C)(P<0.05).The average effective rate(ORR) in observation group(T+C+L) was higher than that in control group(T+C), but there was no statistically significant difference(P>0.05).The toxic and side effect was almost based on severe allergic toxicity of paclitaxel, followed by bone marrow suppression induced by paclitaxel combined with carboplatin, hand and foot numbness, muscle and joint pain, and so on, all of which had different degrees of hair loss, as well as hot flashes and night sweats of a few patients, without any other serious allergic reaction.There was no statistically significant difference in side effects between the two groups(P>0.05).Conclusion Compa

关 键 词：来曲唑 紫杉醇 卡铂 复发卵巢上皮癌 

分 类 号：R737.31[医药卫生—肿瘤]